On April 22, 2026, the U.S. Food and Drug Administration (FDA) implemented new regulatory requirements under the Modernization of Cosmetics Regulation Act (MoCRA) final rules, mandating independent Voluntary Cosmetic Registration Program (VCRP) registration for cosmetic packaging manufacturers exporting to the U.S. This includes empty bottles, tubes, aerosol cans, and other primary packaging components. The change directly affects cosmetic brands, contract manufacturers, and global packaging suppliers — particularly those engaged in U.S.-bound trade without prior VCRP engagement.

Event Overview

The U.S. FDA formally activated MoCRA-related implementation rules on April 22, 2026. Under these rules, all cosmetic packaging products intended for import into the United States — including empty containers such as bottles, tubes, and aerosol cans — must be registered under the Voluntary Cosmetic Registration Program (VCRP) by the packaging manufacturer itself. Registration requires submission of a complete ingredient declaration, covering all colorants, preservatives, and nanomaterials used in the packaging (e.g., in inks, coatings, or internal linings). Non-registered packaging will be denied entry at U.S. ports of entry.

Which Subsectors Are Affected

Direct Exporters & Brand Owners

Brands that source finished cosmetic products from third-party manufacturers — especially those using custom-packaged goods — may face shipment delays or rejections if their packaging suppliers have not completed independent VCRP registration. Responsibility for compliance now rests with the packaging manufacturer, not the cosmetic brand, but brand owners remain accountable for supply chain due diligence.

Packaging Manufacturers & Converters

Companies producing cosmetic packaging for export to the U.S. — including bottle molders, tube extruders, aerosol can makers, and label/coating suppliers — are now required to register separately in VCRP. This applies regardless of whether they also produce finished cosmetics. Submission of full ingredient data for all formulation-relevant packaging components is mandatory.

Contract Manufacturing Organizations (CMOs)

CMOs that integrate packaging into final product assembly must verify VCRP status of each packaging component supplier. Under current guidance, CMOs cannot substitute their own VCRP registration for that of upstream packaging vendors — each packaging manufacturer must hold its own active registration.

Logistics & Customs Service Providers

Freight forwarders and customs brokers handling cosmetic imports must now confirm VCRP registration evidence (e.g., VCRP facility ID) for packaging items listed on commercial invoices or packing lists. Absence of valid registration may trigger FDA refusal-to-admit notices during entry review.

What Relevant Companies or Practitioners Should Focus On Now

Confirm VCRP eligibility and registration scope for packaging-specific activities

Manufacturers should verify whether their packaging production falls within FDA’s definition of “cosmetic packaging” under MoCRA — including any functional or compositional contact with cosmetic formulations (e.g., inner coatings, printed inks, barrier layers). Not all packaging is automatically in scope, but FDA’s current interpretation includes components that may migrate substances into the product.

Prepare and validate ingredient disclosures for non-cosmetic materials

Unlike finished cosmetics, packaging materials often contain industrial-grade additives (e.g., plasticizers, UV stabilizers, pigment dispersants) not previously declared to FDA. Firms must compile full composition data — including CAS numbers and concentration ranges where feasible — for all colorants, preservatives, and nanomaterials present in packaging substrates or applied layers.

Review supply chain contracts and allocate VCRP responsibility explicitly

Brand owners and CMOs should update procurement agreements to assign VCRP registration obligations to packaging suppliers — including timelines, documentation handover, and liability for non-compliance. Relying on past practice or assumed coverage under a brand’s existing VCRP listing is no longer sufficient.

Monitor FDA’s updated VCRP portal functionality and guidance updates

The FDA has indicated ongoing enhancements to the VCRP electronic submission system to accommodate packaging-specific fields. Firms should track official FDA communications (e.g., Federal Register notices, VCRP FAQs) for changes in data format requirements, validation protocols, or phased enforcement expectations beyond April 22, 2026.

Editorial Perspective / Industry Observation

From an industry perspective, this requirement signals a structural shift in FDA’s oversight approach: cosmetic packaging is now treated as a distinct regulatory entity under MoCRA, rather than a passive component of finished product compliance. Analysis来看, this reflects growing regulatory attention to indirect exposure pathways — particularly migration risks from packaging into cosmetic formulations. Observation来看, the rule appears designed less as an immediate enforcement tool and more as a foundational data-gathering mechanism; FDA has not yet published inspection or audit protocols specific to packaging registrants. Current更值得关注的是 how consistently CBP officers apply the refusal-to-admit standard at ports — early enforcement patterns will clarify whether the rule functions primarily as a documentation gate or a substantive safety review.

Conclusion

This regulation marks the first mandatory, manufacturer-level compliance obligation specifically targeting cosmetic packaging in U.S. law. It does not introduce new safety standards per se, but it establishes traceability and transparency as prerequisites for market access. For affected firms, the requirement is best understood not as a one-time filing task, but as the onset of sustained regulatory accountability for packaging composition — a development aligned with broader global trends in extended producer responsibility.

Information Sources

Main source: U.S. FDA Final Rule on MoCRA Implementation (published in Federal Register, effective April 22, 2026). Ongoing policy details, including VCRP portal updates and enforcement guidance, remain subject to further FDA announcements and are currently under observation.